Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Personalis Inc(PSNL)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for PSNL
10/22/2026: PSNL (5-star) is currently NOT-A-BUY. Pass it for now.
Personalis is a genomics company focused on advanced tumor profiling and liquid biopsy diagnostics, primarily serving biopharma partners and oncologists. The company’s core strength lies in its NeXT platform, which provides deep, comprehensive genomic data that differentiates it from smaller-panel competitors. Its growth story hinges on successfully scaling the clinical adoption of its NeXT Personal liquid biopsy test. However, the company faces significant risks, including intense competition from larger firms and an ongoing need to manage high cash burn while proving commercial viability. It may suit growth-oriented investors with a high risk tolerance who are looking for exposure to the evolution of personalized cancer diagnostics.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers exposure to high-growth genomics trends, but requires significant progress in commercial adoption to justify its growth profile. |
| Momentum investor | Strong fit while signal remains positive | Momentum investors may favor the stock during periods of technical breakthroughs or positive commercial announcements, provided an upturn signal is present. |
| Value investor | Weak fit | The company's current financial profile, characterized by ongoing operating losses and high capital requirements, does not align with traditional value investing. |
| Dividend investor | Weak fit | Personalis does not pay a dividend and is not expected to do so in the near term. |
| Low-risk investor | Weak fit | The stock exhibits significant volatility and business-model risk inherent to early-stage biotechnology firms. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock is subject to significant price swings due to its small market capitalization and biotech sector sensitivity. |
| Valuation risk | Medium / high | Future growth expectations are highly priced into the stock, leaving little margin for error in execution. |
| Competition risk (diagnostics/sequencing) | High | The company faces intense competition from larger, better-funded incumbents like Guardant and Natera. |
| Business quality | Medium | While the technology is advanced, the company is still in a phase of establishing a sustainable, recurring revenue business model. |
| Dividend income | Low / none | There is no dividend income for investors. |
| Execution risk | Medium / high | Success depends on scaling commercial operations and proving clinical superiority in competitive markets. |
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Highly Choppy
The stock has experienced frequent, large price swings that make its near-term movement less predictable.
Analysis of Past Performance
Type Stock | Historic Profit 74.06% | Avg. Invested days 22 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 10/22/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.70B USD | Price to earnings Ratio - | 1Y Target Price 15.17 |
Price to earnings Ratio - | 1Y Target Price 15.17 | ||
Volume (30-day avg) 2.3M shares | Beta 2.32 | 52 Weeks Range 4.96 - 18.89 | Updated Date 10/22/2026 |
52 Weeks Range 4.96 - 18.89 | Updated Date 10/22/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.09 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Biopharma Services | Revenue generated from sequencing and data analysis services provided to pharmaceutical companies for clinical trials. | Most revenue currently comes from B2B partnerships with drug developers, which can be lumpy. |
| Clinical Diagnostics | Revenue from diagnostic testing products like NeXT Personal for patient monitoring. | This is the primary long-term growth engine, targeting routine clinical adoption by oncologists. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1.57B | Price to Sales(TTM) 24.37 |
Enterprise Value 1.57B | Price to Sales(TTM) 24.37 | ||
Enterprise Value to Revenue 22.57 | Enterprise Value to EBITDA -0.03 | Shares Outstanding 106.80M | Shares Floating 86.37M |
Shares Outstanding 106.80M | Shares Floating 86.37M | ||
Percent Insiders 26.15 | Percent Institutions 66.79 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.